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Abstract
Tumor cells have evolved effective strategies to escape the host immune response. The objective of this study was to
determinewhether tumor cells can condition endothelial cells in a specific manner to prevent subsequent adhesion of
polymorphonuclear neutrophils (PMNs) and/or peripheral blood lymphocytes (PBLs). Human umbilical vein endothelial
cells (HUVECs) and UKF-NB-4 neuroblastoma tumor cells were established in coculture on opposite sides of porous
transwell filters. After 24 hours with and without HUVEC conditioning, PMNs or PBLs were added to the HUVEC
monolayer. Adhesion to conditioned HUVEC versus adhesion to nonconditioned HUVEC was compared. Effects on
endothelial CD44v4, CD44v5, CD44v7, intercellular adhesion molecule 1 (ICAM-1), E-selectin, and vascular cell adhe-
sion molecule 1 (VCAM-1) adhesion receptor expression were analyzed by flow cytometry, intracellular signaling
proteins of the mitogen-activated protein kinase pathway and protein kinase C (PKC) subtypes quantified by Western
blot analysis. Endothelial conditioning led to a distinct reduction in PMN but not in PBL adhesion to HUVEC. CD44
was significantly reduced, whereas ICAM-1, E-selectin, and VCAM-1 were not altered during HUVEC conditioning.
Antibody blockade against CD44v4, CD44v5, and CD44v7 inhibited PMN but not PBL binding. The observed effects
were caused by direct tumor cell–HUVEC contact because addition of isolated tumor cell membrane fragments but
not of soluble cell culture supernatant to HUVEC induced the CD44 receptor loss. PKCα activity was strongly en-
hanced in conditioned HUVEC. Blocking PKC prevented the reduction in PMN binding, indicating that this protein
is involved in PMN adhesion regulation. A novel tumor escape strategy is presented here. Cell contact–dependent
adhesion of tumor cells to the vascular wall promotes down-regulation of endothelial CD44 receptor expression,
impairing an effective neutrophil attack.
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Introduction
Recent insights into the molecular and cellular mechanisms underlying
cancer development have revealed that immune cells functionally regulate
epithelial cancer development and progression. Although the immune
response depends on phenotype and spatial distribution of infiltrating
cells, leukocytes found in and around developing tumors are thought
to be an attempt by the host to eradicate transformed neoplastic cells.
Lymphocyte populations are considered to be key cells in the im-
mune system for tumor surveillance [1]. Polymorphonuclear neutro-
phils (PMN), the most abundant circulating blood leukocytes, have
received little attention. Although it is still controversial how PMN
may operate within the tumor tissue, recent studies have suggested
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that PMN can reject tumors by directly killing the tumor cells, by
destroying tumor vessels and matrix, by inhibiting angiogenesis, or
by inducing local inflammation [2–4].
On the basis of the observation that leukocyte infiltration into tumors
may be associated with improved prognosis [5], immunodirected anti-
tumor strategies, that is, adoptive or vaccination protocols, have been
developed to treat cancer [6,7]. Unfortunately, immunotherapy has not
been as effective as anticipated. The reasons for the disappointing results
have not yet been fully elucidated, although several hypotheses exist.
Leukocytes must attach to and traverse the vascular endothelium
to infiltrate from the bloodstream into the tumor tissue. Therefore, an
attractive explanation might be that escape mechanisms have been
evolved by the tumor cells to avoid leukocyte–endothelial cell inter-
action. Consequently, immune cells may become unable to migrate
into tumor sites and may not be capable of destroying the tumor. In-
deed, leukocyte delivery and adhesion were found to be reduced in
tumor microvessels [8,9], and an in vivo microcirculation model re-
vealed significantly diminished leukocyte-endothelium interaction in
the tumor tissue compared with the healthy tissue [10].
It is not fully understood why immune cells are unable to traverse
the vascular wall and eradicate the tumor. We speculated that tumor–
endothelial cell cross talk leads to distinct alterations of the local vascula-
ture, which prevents subsequent leukocyte transmigration. To address this
issue, a three-culture assay was established in which human vascular
endothelial cells were conditioned by tumor cells, and the adhesion capac-
ity of isolated lymphocytes or PMN to endothelium was then assessed.
The results show, for the first time, that mechanical contact be-
tween tumor cells and endothelium induces distinct down-regulation
of CD44 adhesion receptors (particularly CD44v4 and CD44v5
splice variants) on endothelial cells, leading to subsequent blockade
of CD44-triggered neutrophil attachment. Lymphocytes attached to
endothelial cells in a CD44-independent manner. This novel finding
supplies an intriguing explanation as to how tumors may escape from
PMN attack and PMN-dependent eradication.
Materials and Methods
Cell Cultures
Human umbilical vein endothelial cells (HUVECs) were isolated
from human umbilical veins and harvested by enzymatic treatment
with chymotrypsin. HUVECs were grown in Medium 199 (M199;
Biozol, Munich, Germany), supplemented with 10% fetal calf serum,
10% pooled human serum, 20 μg/ml endothelial cell growth factor
(Boehringer, Mannheim, Germany), 0.1% heparin, 100 ng/ml genta-
micin, and 20 mMHEPES buffer (pH 7.4). Subcultures from passages
2 to 4 were selected for experimental use. For stimulation experiments,
HUVECs were activated with 500 U/ml tumor necrosis factor α
(TNFα; R&D Systems, Wiesbaden, Germany; 6 hours of incubation).
The neuroblastoma (NB) cell lines UKF-NB-3 and UKF-NB-4 were
established from bone marrow metastasis of Evans stage IV NB [11].
UKF-NB-3 and UKF-NB-4 cells were grown and subcultured in
Iscove’s modified Dulbecco’s medium (Seromed, Berlin, Germany)
supplemented with 10% fetal calf serum, 100 IU/ml penicillin, and
100 μg/ml streptomycin at 37°C in a humidified 5% CO2 incubator.
PMNs were isolated from the venous blood of healthy adult volunteers
by centrifugation on granulocyte separation medium (Polymorphprep,
Nycodenz; Axis-Shield, Oslo, Norway) and immediately used for ex-
periments. The purity of the neutrophils was greater than 95%, and the
viability was greater than 99% as determined by Trypan blue exclusion.
Peripheral blood lymphocytes (PBLs) were isolated by Ficoll-Hypaque
(Biochrome, Berlin, Germany) centrifugation and were resuspended
at a density of 1 × 106 cells per milliliter of HUVEC medium.
PMN and PBL Coculture Adhesion Assay
Six-well plates (Sarstedt, Nürnbrecht, Germany) were equipped
with porous cell culture membrane inserts with pore diameters of
3 μm, a pore density of 3 × 106/cm2, and an effective culture area of
4.2 cm2 (Nunc,Wiesbaden, Germany). The inserts were turned upside
down, and 1 × 106 UKF-NB-4 or UKF-NB-3 cells per milliliter were
poured onto the lower surface of the membrane units and allowed to
settle for 12 hours at 37°C in a humidified 5% CO2 incubator. Inserts
were then turned right side up, transferred to new six-well plates that
were filled with a 1:1 mixture of NB/HUVEC medium, and 1 × 106
HUVECs per milliliter were added to the upper surface of the mem-
brane units. HUVECs were conditioned by coculture for 24 hours
before the PMN or PBL adhesion assay. In control studies, HUVECs
were incubated on empty inserts. Either 0.5 × 106 PMNs or PBLs per
milliliter were then added to HUVECs for 60 minutes. Subsequently,
nonadherent cells were washed off using phosphate-buffered saline
(Gibco, Karlsruhe, Germany). The remaining cells were detached from
the upper surface of the membrane inserts by Accutase treatment (PAA
Laboratories, Cölbe, Germany), stained with leukocyte-specific anti-
CD45 PerCP monoclonal antibody (clone 2D1; BD Pharmingen,
Heidelberg, Germany), and subjected to flow cytometry (FACscan;
BectonDickinson,Heidelberg, Germany). Sideward scatter (SSC) gating
was set up to display percentage of PMNs or PBLs bound to HUVECs.
The purity of the HUVEC monolayer and contamination with
migrated UKF-NB-3 or UKF-NB-4 were controlled in parallel ex-
periments. Cells grown on the upper surface of the membrane inserts
were detached by Accutase and stained with NB-specific phycoery-
thrin (PE)-conjugated monoclonal antibody anti-CD56, which detects
the neural cell adhesion molecule (NCAM) 120-, 140-, and 180-kDa
isoform (clone 16.2; immunoglobulin G2b [IgG2b]; BD Biosciences,
Heidelberg, Germany). NCAM (CD56) expression was then measured
using a FACscan (FL-2H [log] channel histogram analysis; 1 × 104 cells
per scan). To evaluate background staining of PE-conjugated anti-
CD56, goat-antimouse IgG2b-PE was used. Dot plot quadrant analy-
ses were carried out to display percentage distribution of CD56+
(UKF-NB-3/UKF-NB-4) and CD56− (HUVEC) cells. UKF-NB-3 or
UKF-NB-4 monocultures served as the positive controls.
Endothelial Adhesion Receptor Expression
Monoclonal antibodies were used, directed against CD44 splice
variants (v) CD44v4 (clone VFF-11), CD44v5 (clone VFF-8), and
CD44v7 (clone VFF-9; all fromBenderMedSystems, Eching, Germany)
or directed against CD54 (syn. intercellular adhesion molecule 1
[ICAM-1], clone 15.2), CD62E (syn. E-selectin, clone TEA2/1), and
CD106 (syn. vascular cell adhesion molecule 1 [VCAM-1], clone
1G11.B1; all from Dianova, Hamburg, Germany). The primary anti-
bodies were conjugated with fluorescein isothiocyanate (FITC). Two
different strategies were applied to analyze adhesion receptor expres-
sion on HUVEC in a HUVEC-NB coculture system:
1) UKF-NB-4 cells (1 × 106 cells per ml; total volume, 5 ml) were
added to subconfluent HUVEC monolayers grown in a 75-cm2
culture flask. After 16 hours of incubation, cells were detached by
Accutase treatment, and receptor expression was analyzed by flow
cytometry. To identify the endothelial cell population, the cell
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mixture was double stained using a monoclonal antibody directed
against UKF-NB-4 (anti-CD56) and monoclonal antibodies di-
rected against the receptor in question. Cells were washed twice
in blocking solution (phosphate-buffered saline, 0.5% bovine
serum albumin) and subsequently incubated for 60 minutes at
4°C with the monoclonal antibody anti–CD56-PE. Cells were
then marked with FITC-conjugated monoclonal antibodies anti-
CD44v4, anti-CD44v5, anti-CD44v7, anti-CD54 (ICAM-1),
anti-CD62E (E-selectin), or anti CD106 (VCAM-1). To explore
ICAM-1, VCAM-1, and E-selectin, HUVECs were prestimulated
for 6 hours with 500 U/ml TNFα. Dot plot quadrant analyses
(SSC gating) was carried out to obtain two distinct cell populations,
population I (CD56+) as UKF-NB-4 cells and population II
(CD56−) as HUVEC. Adhesion receptor expression of HUVEC
was then detected by FACscan analysis (FL-1 [log] channel
histogram analysis; 1 × 104 cells per scan). To evaluate the back-
ground staining of FITC-labeled antibodies, a mouse IgG1-FITC
was used as an isotype control.
2) A membrane-separated coculture of UKF-NB-4 and HUVEC
cells was established, in which UKF-NB-4 cells adhered to the
lower surface of the membrane inserts and HUVECs were in-
cubated on the upper surface of the membrane inserts (see pre-
vious paragraphs). HUVECs were detached from the upper
surface of the membrane inserts by Accutase treatment, stained
with monoclonal antibodies as indicated previously, and sub-
jected to flow cytometry (FL-1 [log] channel histogram analysis).
Isolation of NB Plasma Membranes
UKF-NB-4 were pooled and washed in cold STM buffer (0.25 M
sucrose, 5 mM Tris, pH 8.0, 0.5 mM MgCl2), minced, and homo-
genized using a Dounce homogenizer. Nuclei and cell debris were
removed by centrifugation at 280g for 5 minutes. The supernatant
was saved, and the pellet was resuspended in 0.25 M STM using a
Dounce homogenizer. The suspension was again centrifuged as previ-
ously mentioned. First and second supernatants were combined and
Figure 1. Fluorometric analysis of CD56 surface expression on HUVECs (A) versus UKF-NB-4 cells (B). Both cell types were stained
separately with PE-conjugated monoclonal antibody anti-CD56, which detects the NCAM 120-, 140-, and 180-kDa isoforms. CD56 ex-
pression is depicted as dot blot (sideward scatter vs CD56) and FL-2H (log) channel histogram analysis. (C) A 24-hour contamination rate
of CD56− HUVEC by traversed CD56+ UKF-NB-4 cells in the transwell coculture assay. Cell populations growing on the upper surface of
8-μm pore-sized membranes were stained with an anti-CD56 monoclonal antibody and dot blot analysis carried out by a FACscan. One
representative of three tests is shown.
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centrifuged at 1500g for 10 minutes. The resulting pellets, containing
the plasma membrane fraction, were resuspended in 0.25 M STM and
adjusted to 1.18 g/cm3 sucrose density using 2M sucrose in 5 mMTris,
pH 8.0, and 0.5 mMMgCl2. Sucrose density was determined at room
temperature with an Abbe refractometer. Samples were transferred to
ultracentrifuge tubes and overlaid with 0.25 M sucrose. After centri-
fugation for 60 minutes at 82,000g in a Beckman L5-65 centrifuge
(SW 28 rotor), the pellicle at the interface was collected and resus-
pended in sufficient 0.25 M sucrose to obtain a density of 1.05 g/cm3.
Protein concentration was determined by the Lowry method, using
bovine serum albumin as a standard. One hundred micrograms
of protein per milliliter was added to subconfluent HUVECs for
16 hours, and endothelial adhesion receptor expression was evaluated
by flow cytometry as indicated previously.
CD44 Blocking Experiments
HUVECs were transferred to six-well plates and grown to sub-
confluency. They were then preincubated for 60 minutes with
anti-CD44v4, anti-CD44v5, or anti-CD44v7 monoclonal anti-
bodies at a concentration of 50 μg/ml each followed by repeated
washing with fresh HUVEC medium. Controls remained untreated.
Isolated PMNs or PBLs (1.5 × 105 cells per milliliter) were added to
the HUVEC monolayer for 60 minutes. Subsequently, nonadherent
tumor cells were washed off using warmed (37°C) culture medium.
The remaining cells were fixed with 1% glutaraldehyde. In each ex-
perimental setting, adherent tumor cells were counted in five differ-
ent fields of a defined size (5 × 0.25 mm2) using a phase-contrast
microscope, and the mean cellular adhesion rate was calculated.
Analysis of Intracellular Signaling by Western Blot Analysis
Monoclonal antibodies were used and directed against proteins indi-
cated subsequently: extracellular signal–regulated kinase 1 (ERK1,
IgG1, clone MK12; 1:5000), ERK2 (IgG2b, clone 33; 1:5000), and
phospho–ERK1/2 (IgG1, clone 20A; 1:1000) were obtained from
BD Biosciences. PKCα (IgG2b, clone 3; 1:1000), PKCβ (IgG2b, clone
36; 1:250), PKCδ (IgG2b, clone 14; 1:500), PKCε (IgG2a, clone 21;
1:1000), and PKCι (IgG2b, clone 23; 1:250) were from BD Bio-
sciences. Phospho-PKCα (rabbit, polyclonal; 1:1000) was from Milli-
pore, Schwalbach, Germany. Phospho-PKCε (rabbit, polyclonal;
1:1000) and phospho-PKCι (rabbit, polyclonal; 1:1000) were from
Abcam (Cambridge, United Kingdom). Anti–β-actin monoclonal anti-
body was obtained from Sigma (Taufenkirchen, Germany).
UKF-NB-4 cells (1 × 106 cells per milliliter; total volume, 5 ml)
were added to subconfluent HUVEC monolayer grown in a 75-cm2
culture flask. After 16 hours of incubation, cells were detached by
Accutase treatment. To isolate HUVECs, the cell suspension was
Figure 2. PMNs’ versus PBLs’ adhesion to HUVECs. Isolated PMNs or PBLs were added to preconditioned HUVECs as described in the
Materials and Methods section. Anti-CD45 PerCP monoclonal antibody was then used to distinguish between HUVECs (R1) and PMNs
(R2; A) or PBLs (R2; B) by flow cytometry (SSC gating) and to display the percentage of PMNs or PBLs, which bound to HUVECs (%R2).
Controls, indicating PBL/PMN binding to unstimulated or TNFα-stimulated HUVECs, were each set to 100%. “HUVEC/NB” indicates percent
PBL/PMN binding to preconditioned HUVEC; “HUVECact/NB” indicates percent PBL/PMN binding to preconditioned, TNFα-activated
HUVECs (C). One representative of n = 6 experiments. *Significantly different from controls. #Significantly different from HUVEC-NB.
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incubated with magnetic beads (Dynabeads M450 IgG1; Dynal
Biotech GmbH, Hamburg, Germany) conjugated to an anti-CD56
monoclonal antibody (negative selection). The selected popula-
tion obtained by this procedure was routinely greater than 95% by
flow cytometry.
HUVEC cell lysates were applied to a 7% polyacrylamide gel and
electrophoresed for 90 minutes at 100 V. The protein was then trans-
ferred to nitrocellulose membranes. After blocking with nonfat dry
milk for 1 hour, the membranes were incubated overnight with the
antibodies listed previously. HRP-conjugated goat-antimouse IgG
(Upstate Biotechnology, Lake Placid, NY; dilution 1:5000) served as
the secondary antibody. The membranes were briefly incubated with
enhanced chemiluminescence detection reagent (Amersham/GE
Healthcare, München, Germany) to visualize the proteins and exposed
to an x-ray film (Hyperfilm EC; Amersham).
Statistics
All experiments were performed three to six times. Statistical signifi-
cance was investigated by the Wilcoxon–Mann-Whitney U test. Dif-
ferences were considered statistically significant at P < .05.
Results
Preconditioning of HUVECs and Selection of Membrane
Pore Size
Tumor cell invasion through endothelium requires direct cell-to-
cell contact. To allow direct contact and optimum conditioning of
HUVECs by the tumor cells, a membrane-separated coculture was
established, in which NB tumor cells adhered to the lower surface and
HUVEC to the upper surface of membrane inserts. The objective was to
promote a high degree of interaction between the two cell types but to
leave the HUVEC monolayer intact (necessary for the subsequent PBL
or PMN binding experiments). Therefore, a membrane pore size was
chosen to guarantee the extension of tumor cell protrusions through
the pores while restricting the tumor cell bodies to the seeded side. Three
different pore-sized membranes were applied in initial studies, namely,
0.22, 3, or 8 μm. A 24-hour contamination rate of HUVECby traversed
NB cells was established by staining the cell population on the upper sur-
face of the membrane inserts with an anti-CD56 monoclonal antibody.
CD56 had previously been demonstrated to be exclusively expressed
on NB cells but not on HUVEC (Figure 1, A and B, representative
of UKF-NB-4). Anti-CD56 staining was therefore well qualified to
discriminate between NB and endothelial cells and to quantify the
percentage of NB that had been growing into the HUVEC monolayer.
UKF-NB-4 cells easily traversed the 8-μm pores leading to a high
contamination of the HUVEC monolayer (mean contamination rate,
24 ± 8%). No UKF-NB-3 or UKF-NB-4 cells passed through the
0.22-μm pores, but these pores were too small to allow sufficient tumor
cell–endothelial cell contact. Optimum results were obtained with the
3-μm membrane inserts and a tumor cell contamination below 2%
(Figure 1C , representative of UKF-NB-4). Therefore, adhesion of
PBL or PMNmeasured after the 24-hour preconditioning phase could
be related to HUVECs, and irregular interaction of leukocytes with NB
cells could be excluded. Consequently, in all further experiments, the
3-μm membrane inserts were used.
Figure 3. Analysis of endothelial adhesion receptor expression. HUVECs were cocultivated with UKF-NB-4. CD56+ populations were gated
out by flow cytometry (R1 vs R2) as described in the Materials and Methods section (A). E-selectin (CD62E), ICAM-1 (CD54), and P-selectin
(CD106; B), and CD44v4, v5, and v7 (C) of CD56-negative HUVECswere then evaluated by FACS analysis (MFU indicatesmean fluorescence
units). “HUVEC” depicts isolated, nonconditioned endothelial cells (controls), MFU of which were set to 100%. “HUVEC/NB” indicates endo-
thelial cells preconditioned by UKF-NB-4 tumor cells. One representative of n=6 experiments. *Significantly different from control HUVECs.
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Tumor Cell–Endothelial Cell Interaction Alters PMN
But Not PBL Adhesion
HUVECs were preconditioned for 24 hours with UKF-NB-3 or
UKF-NB-4 on 3-μm membrane inserts, and lymphocytes or PMNs
were then added to the HUVEC monolayer. PBLs or PMNs were
subsequently gated by flow cytometry (population R2; Figure 2, A
and B), and the percentage adhesion was calculated. Cross talk of
HUVECs with UKF-NB-3 or UKF-NB-4 resulted in a selective and
significant blockade of PMNs but not of PBLs binding to HUVECs
compared with HUVEC controls that were cultivated on empty inserts
(Figure 2C , representative of UKF-NB-4). Prestimulation of HUVECs
with TNFα led to a further reduction of PMN binding. Separate cul-
tivation of HUVECs and NBs, that is, HUVECs grown on the mem-
brane insert and UKF-NB-3 or UKF-NB-4 on the bottom of the
six-well plate, did not influence PBL or PMN binding behavior (data
not shown).
Analysis of Adhesion Receptor Expression
Endothelial adhesion receptors known to be involved in leuko-
cyte recruitment were analyzed next. UKF-NB-4 cells were added
to HUVEC for 16 hours, and HUVEC populations were separated
thereafter by flow cytometry (Figure 3A). Expression levels of CD62E
(E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1) were not
altered in TNFα-stimulated HUVECs cultivated in the presence of
UKF-NB-4 cells (Figure 3B). However, CD44 splice variants CD44v4,
CD44v5, and CD44v7 were all significantly downregulated on
HUVECs in the coculture system compared with HUVECs that
were seeded without UKF-NB-4 (Figure 3C ). Effects on endothelial
CD44v4, CD44v5, and CD44v7 adhesion receptor expression were
similar between HUVECs pretreated and not pretreated with TNFα.
CD44 expression was further evaluated in the porous membrane co-
culture assay. HUVEC–UKF-NB-4 interaction led to distinct reduc-
tions of CD44v4, CD44v5, and CD44v7 levels (Figure 4A). To
address the question of whether receptor loss was caused by direct
contact of endothelial cells with tumor cells or indirectly by soluble
mediators released into the cell culture supernatant, HUVECs were
treated with isolated UKF-NB-4 membrane fragments, and CD44 ex-
pression was then analyzed. On the basis of this technique, CD44v4,
CD44v5, and CD44v7 were all found to be diminished on HUVECs
compared with untreated controls (Figure 4B). Separate cultivation of
HUVECs (grown on the membrane insert) and UKF-NB-4 (grown on
the bottom of the six-well plate) or stimulation of HUVECs with cell
culture supernatant taken from a HUVEC–UKF-NB-4 coculture
system did not change CD44 expression (data not shown).
Figure 4. Evaluation of CD44 expression level on HUVECs. HUVECs and UKF-NB-4 cells were grown on opposite sides of 3-μm cell
inserts and endothelial CD44 expression analyzed thereafter (A), or HUVECs were subjected to isolated UKF-NB-4 membrane fragments
and CD44 expression was evaluated subsequently (B). CD44 analysis was carried out by a FACscan using the appropriate monoclonal
antibodies as listed in the Materials and Methods section (MFU indicates mean fluorescence units). Nonconditioned HUVECs served as
controls; MFU values were set to 100%. One representative of six experiments is shown. *Significant difference from control HUVECs.
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CD44 Receptor Blockade Reduces PMN Binding
To evaluate the physiological relevance of CD44 adhesion recep-
tors, HUVECs were incubated with monoclonal antibodies directed
against CD44v4, CD44v5, or CD44v7, and leukocyte adhesion ca-
pacity was then measured. Blocking of CD44v4 and CD44v5, but
not of CD44v7, strongly reduced the amount of PMN adhering to
HUVEC (Figure 5, left). When HUVECs were preactivated with
TNFα, blocking of each CD44 receptor subtype, namely, CD44v4,
CD44v5, and CD44v7, resulted in a significant reduction in PMN’s
adhesion to HUVECs (Figure 5, right). Binding of PBLs to HUVECs
was not influenced by CD44 blocking (Figure 5, down).
HUVEC Tumor Cell Cross Talk Modifies
Endothelial Cell Signaling
The intracellular signaling cascade in HUVEC after exposure to
UKF-NB-4 cells was examined by purifying HUVEC from the co-
culture system by magnetic bead separation (Figure 6A) and subjecting
them to Western blot analysis (Figure 6B). Conditioning of HUVECs
by UKF-NB-4 cells caused a moderate reduction of ERK1 and ERK2
proteins. No changes were seen in ERK1/2 activation. PKCβ and PKCδ
were not detected in HUVECs. PKCα and PKCι were slightly elevated
in HUVECs exposed to UKF-NB-4, whereas PKCε remained un-
changed. Notably, phosphorylated PKCα was drastically enhanced in
HUVECs when cocultured withUKF-NB-4 cells. Phosphorylated PKCι
was upregulated moderately compared with the controls (Figure 6B).
Incubation of conditioned HUVECs with the PKC inhibitor bisin-
dolylmaleimide I (BIM I, 2.5 μM)prevented the loss of PMNadhesion,
which was induced by conditioned HUVECs not treated with BIM I
(Figure 6C).
Discussion
Down-regulation of endothelial CAM and selectin adhesion molecules
by angiogenic factors has recently been shown to be a potent escape
mechanism used by disseminating tumor cells to protect themselves
against T-lymphocyte attack [9]. A novel mechanism of endothelial cell
anergy is presented here. On the basis of a three–cell culture assay, evi-
dence is shown that tumor cell–endothelial cell communication triggers
down-regulation of CD44 molecules on endothelial cells, resulting in
diminished PMN-HUVEC interaction. CD44 down-regulation was
Figure 5. CD44 blockade prevents PMNs’ adhesion to HUVECs. PMNs or PBLs were added to HUVEC monolayers (nonactivated vs TNFα
activated) and then added at a density of 1.5 × 105 cells per milliliter for 60 minutes. HUVECs have been preincubated for 60 minutes with
anti-CD44v4, anti-CD44v5, or anti-CD44v7 monoclonal antibodies. Controls remained untreated. Nonadherent PMNs or PBLs were washed
off in each sample; the remaining cells were fixed and counted in five different fields (5 × 0.25 mm2) using a phase-contrast microscope.
Mean values were calculated from five counts. Mean adhesion capacity is depicted as counted cells per squared millimeter and related to
control values that were set at 100%. One representative of six experiments is shown. *Significant difference from controls.
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caused by direct intercellular cross talk and not by soluble mediators
because sensitization of endothelium by isolated tumor cell membrane
fragments but not by soluble cell culture supernatant was responsible for
the CD44 receptor loss. Therefore, the attenuation of vascular CD 44
expression may prevent immune surveillance of transmigrated tumor
cells by PMN.
PMNs’ impact on tumor destruction has not been completely eluci-
dated, making final interpretation of the present results difficult.
Nevertheless, several NB cell models document the importance of
PMN attraction in tumor cell lysis and growth inhibition [12]. Accu-
mulation of PMN has resulted in complete growth arrest of large,
established tumors in NB-bearing animals [13], and Takamizawa
et al. has reported targeting and destruction of NB clones by PMN
in vivo, even in immune compromised hosts [14]. Antitumor character-
istics of PMN have also been demonstrated in tumors other than NB.
Neutrophil-depleted mice developed significantly larger tumors after
subcutaneous injection of melanoma cells compared with control ani-
mals with intact PMN. Reactivation of neutrophils significantly delayed
melanoma formation [15]. Also, PMNs have been shown to play a crit-
ical role in eradicating malignant mesothelioma or lung carcinoma cells
in vivo, whereas complete abrogation of antitumor immunity has been
seen in the absence of PMNs [16]. The mechanism of endothelial cell
anergy presented in this report may therefore not be restricted to NB
cells but rather may be valid for further tumor entities.
CD44 receptors are detectable on both PMNs and endothelial or
epithelial cells. However, it has been demonstrated that CD44 recep-
tors on PMNs do not play a fundamental role in facilitating PMN
recruitment [17,18]. An elegant study on chimeric mice expressing
CD44 either on their PMNs or on their endothelium presented
evidence showing endothelial CD44 to be crucial for optimal
PMN invasion [19]. In close analogy, rapid CD44 up-regulation on
capillary endothelial cells rather than neutrophil CD44 expression me-
diated transendothelial neutrophil recruitment into the tissue. Endo-
thelial CD44 deficiency led to decreased influx of neutrophils [20].
Accordingly, the blocking studies presented here point to the relevance
of endothelial CD44 expression level in PMN binding control.
The CD44 splice variants v4, v5, and v7 were all downregulated in
HUVECs conditioned withNB cells. However, the strongest alterations
Figure 6. Cell signaling in conditioned versus nonconditioned HUVECs. UKF-NB-4 cells were added to subconfluent HUVEC monolayer
for 16 hours. Cells were then detached from the culture flask by Accutase treatment and HUVECs were isolated by magnetic separation
(negative selection). The selected population (R1) obtained by this procedure was greater than 95% as controlled by flow cytometry (A).
ERK and PKC signaling was explored in control HUVECs and HUVECs preconditioned with UKF-NB-4 cells (HUVEC-NB) by Western blot
analysis (B). β-Actin served as the internal control. One representative of three experiments is shown. (C) Relevance of PKC blocking
for PMNs’ adhesion. A total of 0.5 × 106 PMNs per milliliter were added to preconditioned HUVECs (HUVEC-NB), to preconditioned
HUVECs incubated with the PKC blocking antibody BIM I, or to control HUVECs for 60 minutes as described in the Materials and
Methods section. Bound PMN were identified by flow cytometry using the leukocyte-specific anti-CD45 monoclonal antibody. SSC
gating was set up to display percentage of PMNs that bound to HUVECs (controls = 100%). *Significant difference from controls.
#Significant difference from HUVEC-NB.
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were seen inCD44v4 andCD44v5 expressions. This phenomenonmay
refer to a different significance of CD44 splice variants in initiating en-
dothelial cell anergy. In fact, PMNs attached to unstimulated HUVECs
through CD44v4 and CD44v5 but not through the CD44v7 receptor.
CD44v7-dependent neutrophil adhesion was restricted to TNFα-
stimulated HUVECs. Presumably, both CD44v4 and CD44v5 recep-
tors are the dominant modifiers of transendothelial PMNs trafficking
toward invaded tumor cells. CD44v7 may be considered an additional
compensating mechanism to counteract TNFα-induced (and other
proinflammatory cytokines?) leukocyte and endothelial cell activation.
On the basis of this, it seems logical that PMN binding to TNFα-
activated HUVECs was reduced to a higher extent than PMN binding
to nonactivated HUVECs.
Binding of PBLs to HUVECs was not inhibited in our cell culture
system, although lymphocytes have been described to be strongly in-
volved in the escape of tumors from immune surveillance. Indeed,
several in vitro and in vivo assays have revealed that tumors are able to
block lymphocyte–vessel wall interactions as well. Nevertheless, PBL
attachment seems to be regulated by mechanisms different from those
regulating PMN adhesion. Dirkx et al. [9] and others [21–23] have dis-
covered that lymphocyte invasion is hampered by diminishing the level
of adhesion molecules ICAM-1, VCAM-1, and E-selectin expressed on
endothelial cells. Receptor reduction is governed by exposing the endo-
thelium to soluble angiogenic factors such as vascular endothelial cell
growth factor or basic fibroblast growth factor.
On the basis of these data, suppression of ICAM-1, VCAM-1, and/or
E-selectin by solublemediatorsmight be responsible for preventing lym-
phocyte extravasation toward engrafted tumor cells. We did not analyze
the effect of soluble angiogenic factors on PMN recruitment. However,
mechanical contact of NB cells withHUVECs was obligatory tomodify
CD44 expression and PMN adhesion capacity. In addition, neither cell
culture supernatant taken from preconditioned HUVEC nor direct
tumor cell–HUVEC interaction evoked significant alterations of
ICAM-1, VCAM-1, and E-selectin, which had been attributed to con-
trol PBL trafficking. Taking into account that anti-CD44 monoclonal
antibodies prevented PMNs’ but not PBLs’ attachment toHUVEC, it is
possible that the binding capacity of PBL has not been modified in our
in vitro model. Obviously, different tumor escape mechanisms exist,
which affect the biologic interrelationship between vascular endothelium
and PBL or PMN in two separate ways. Our experiments point to a
direct (i.e., membrane triggered) CD44-dependent induction of PMN
adhesion blockade, which opposes the indirect (i.e., not membrane trig-
gered) CD44-independent modulation of PBL transmigration events.
HUVECs’ contact with NB cells caused enhancement of phosphory-
lated PKCα and moderate up-regulation of activated PKCι in the en-
dothelial cells. No data dealing with this issue are available from the
literature. It is therefore difficult to make a final assessment about
how this particular protein contributes to the regulation of CD44 ex-
pression and PMN binding. Blocking of PKC activity in HUVEC,
which had previously been conditioned by UKF-NB-4, prevented
the loss of PMN attachment seen in the control cocultures. This sug-
gests at least a partial role for PKCα (and PKCι) in suppressing PMN
adhesion. Recently, in good accordance with this view, activation of
PKC in endothelial cells was demonstrated to abolish transendothelial
PMN migration toward a chemoattractant [24]. Still, the impact
of PKC expression level on endothelial cell function remains a matter
of debate. On the basis of a hyperglycemia model, PKCα and PKCε
isoforms positively correlated with PMN adhesion to HUVEC [25],
whereas a further vascular inflammation model did not reveal any effect
of PKC inhibition on PMN recruitment [26]. The putative role of
PKCα on PMN recruitment may not be comparable in tumors and
in inflammation [27]. Therefore, additional studies are required to clar-
ify whether therapeutic blocking of PKCα could become an important
tool to reactivate PMN migration.
Evidence that cell contact-dependent adhesion of tumor cells to the
vascular wall promotes down-regulation of endothelial CD44 receptor
expression and prevents subsequent CD44 triggered PMN binding to
endothelial cells is presented here. This may serve as a tumor-protecting
mechanism by impairing the development of an effective neutrophil
attack. Silencing PKCα overcomes tumor escape processes, suggesting
a newmolecularmechanism towardwhich novel therapeutic approaches
for cancer might be directed.
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